Truist Securities Maintains Buy on Eli Lilly, Raises Price Target to $600
Portfolio Pulse from jenniferd'souza@benzinga.com
Truist Securities analyst Robyn Karnauskas maintains a Buy rating on Eli Lilly (LLY) and raises the price target from $525 to $600.
August 09, 2023 | 2:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities maintains a Buy rating on Eli Lilly and raises the price target from $525 to $600.
The raised price target by Truist Securities indicates a positive outlook for Eli Lilly. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100